@article{PAR00030337,
  title = {{W}illingness to participate in a long-acting injectable cabotegravir {HIV} pre-exposure prophylaxis study among men who have sex with men in the {F}rench {ANRS}-{PREVENIR} cohort},
  author = {{E}ubanks, {A}. and {H}oyer, {M}. and {S}ow, {A}. and {M}ora, {M}. and {A}ssoumou, {L}. and {B}eniguel, {L}. and {G}hosn, {J}. and {J}ones, {J}. {C}. and {C}ostagliola, {D}. and {S}pire, {B}. and {M}olina, {J}. {M}. and {L}iegeon, {G}. and {S}agaon {T}eyssier, {L}uis and {P}roti{\`e}re, {C}.},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjectives {D}espite the wide implementation of {HIV} oral pre-exposure prophylaxis (o{P}r{EP}), uptake, adherence and persistence issues remain. {L}ong-acting injectable cabotegravir ({CAB}-{LA}) is a promising new {P}r{EP} {HIV} prevention option. {H}owever, little is known about o{P}r{EP} users' interest in it. {W}e investigated men who have sex with men ({MSM}) o{P}r{EP} users' willingness to participate ({W}t{P}) in a {CAB}-{LA} {P}r{EP} study in {F}rance.{M}ethods {W}e designed a cross-sectional questionnaire ('{N}ew{P}r{EP}') to evaluate attitudes to {CAB}-{LA} of daily and event-driven o{P}r{EP} users participating in the {ANRS}-{PREVENIR} cohort study (2017-2025). {T}he outcome, {W}t{P}, was dichotomised into '{W}illing' (absolutely/probably) or '{U}nwilling' (probably not/absolutely not/{I} would like to discuss this with my doctor before making a decision). {W}e used multivariate logistic {B}ayesian model averaging to estimate factors associated with {W}t{P}.{R}esults {O}f the 1555 {MSM} followed in {ANRS}-{PREVENIR} in {F}ebruary 2023 with baseline data, 879 (57%) answered the {N}ew{P}r{EP} questionnaire. {M}edian age and follow-up time were 38 and 4.7 years, respectively; 37% and 22% were on daily- and event-driven o{P}r{EP}, respectively; 41% used a combination of both regimens. 64% had heard of {CAB}-{LA} {P}r{EP}, and 43% were {W}t{P} in a related study. {M}ultivariate results showed that willing participants were younger and more likely to have heard of {CAB}-{LA}, to use daily o{P}r{EP} exclusively or in combination, to find it difficult to adhere to their regimen, to engage in chemsex, to trust their doctor and to be more interested in {P}r{EP} effectiveness than in the administration mode. {T}hey were less likely to perceive the obligatory 2-monthly hospital visits for {CAB}-{LA} {P}r{EP} as constraining, to be scared of injections and to fear long-acting medications.{C}onclusions {W}t{P} in a {CAB}-{LA} study among {MSM} o{PREP} users was moderate but concentrated among those with the greatest need. {T}his highlights the need to enable free distribution. {F}uture studies should evaluate adherence and retention in long-acting i{P}r{EP}.},
  keywords = {{HIV} ; {PREP} ; {C}ohort {S}tudies ; {PUBLIC} {HEALTH} ; {S}ocial {S}ciences ; {FRANCE}},
  booktitle = {},
  journal = {{S}exually {T}ransmitted {I}nfections},
  volume = {[{E}arly access]},
  numero = {},
  pages = {},
  ISSN = {1368-4973},
  year = {2025},
  DOI = {10.1136/sextrans-2025-056662},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00030337},
}